Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Lamisil, Lamisil At. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Terbinafine (sold as Lamisil, Lamisil At), first approved Apr 29, 1998, with 1 new use approved and 0 published complete response letters.
First approved: Apr 29, 1998
Applications: 2
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $11.5M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Terbinafine HCl
Part D
$11.5M
+19%
465,333
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
TERBINAFINE HCL 250 MG TABLET: $0.143 per unitGeneric · -5% in a year
Clinical Trials
12 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
